RVMD
Revolution Medicines Inc
A maker of experimental medicines designed to target RAS proteins, the 'switches' that drive pancreatic, lung, and colorectal cancers — proteins long dubbed 'undruggable.' It was founded in 2014 by three chemical biologists, including the University of California scientist Kevan Shokat, whose lab cracked how to reach RAS, and was originally named Midasyn. Its employees call themselves 'Revolutionaries.'
CONVERTIBLEUnderlying: RVMD 0.5 05/01/33CUSIP: 76155XAA8HealthcareUS1 derivative reporter
0.50% Convertible Senior Notes due 2033
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
